(Total Views: 113)
Posted On: 02/16/2017 8:34:09 PM
Post# of 63743
ZSAN new volume breakout $3.07
Nasdaq CM
Website
2/13/17
Zosano Pharma Announces 3.8mg Dose of M207,
its Novel Transdermal Therapeutic,
Meets BothCo-primary Endpoints in the ZOTRIP
Pivotal Efficacy Trial in Migraine
10-Q 11/9/16
Ultra low float
Shares Outstanding 16.82M
Float 8.43M
% Held by Insiders 57.44%
% Held by Institutions 35.10%
Shares Short 293.58k
Short Ratio 1.08
Short % of Float 2.87%
Shares Short (prior month) 299.36k
Last ten trades
Stock technical analysis
100% x 100% Strong Buy
Zosano Pharma Corporation, a clinical stage specialty pharmaceutical company, develops a proprietary transdermal microneedle patch system to deliver drug formulations through the skin for the treatment of various indications. The companys product candidate is ZP-Triptan, a proprietary formulation of zolmitriptan used for the treatment of migraine, which has completed a Phase I clinical trial. Its product candidates also include ZP-PTH, a proprietary formulation of teriparatide that is used for the treatment of severe osteoporosis; and ZP-Glucagon, a proprietary formulation of glucagon that is intended for the emergency rescue of patients suffering from life-threatening, severe hypoglycemia. The company was founded in 2006 and is headquartered in Fremont, California.
Nasdaq CM
Website
2/13/17
Zosano Pharma Announces 3.8mg Dose of M207,
its Novel Transdermal Therapeutic,
Meets BothCo-primary Endpoints in the ZOTRIP
Pivotal Efficacy Trial in Migraine
10-Q 11/9/16
Ultra low float
Shares Outstanding 16.82M
Float 8.43M
% Held by Insiders 57.44%
% Held by Institutions 35.10%
Shares Short 293.58k
Short Ratio 1.08
Short % of Float 2.87%
Shares Short (prior month) 299.36k
Last ten trades
Stock technical analysis
100% x 100% Strong Buy
Zosano Pharma Corporation, a clinical stage specialty pharmaceutical company, develops a proprietary transdermal microneedle patch system to deliver drug formulations through the skin for the treatment of various indications. The companys product candidate is ZP-Triptan, a proprietary formulation of zolmitriptan used for the treatment of migraine, which has completed a Phase I clinical trial. Its product candidates also include ZP-PTH, a proprietary formulation of teriparatide that is used for the treatment of severe osteoporosis; and ZP-Glucagon, a proprietary formulation of glucagon that is intended for the emergency rescue of patients suffering from life-threatening, severe hypoglycemia. The company was founded in 2006 and is headquartered in Fremont, California.
(0)
(0)Scroll down for more posts ▼
